Study Results Find Different Mechanisms of Action in 2 Immune Checkpoint Inhibitor Regimens
December 18th 2023The differences between the regimens, anti-PD1/CTLA-4 and anti-PD1/LAG-3, can be used to optimize outcomes for patients with melanoma, particularly in those who develop drug resistance.
Read More
Expert: Updates for Zotatifin ER+/HER2- Breast Cancer Treatment
December 15th 2023Douglas Warner, MD, chief medical officer at eFFECTOR, provides a comprehensive overview of zotatifin and its current status in a Phase 1/2 dose escalation and expansion study, with a focus on ER+/HER2- breast cancer.
Watch
Navigating C. Diff During the COVID-19 Pandemic, The Impact of Antibiotic Usage and Surgeries
December 14th 2023Feldman details her experience with C. diff, how the COVID-19 pandemic slowed the timeline of care, and how her surgical history and the use of antibiotics played into the disease’s onset.
Watch
Expert Discusses Navigating Toxicities, Understanding Antibody-Drug Conjugate Adverse Events
December 14th 2023Heather McArthur, MD, clinical director of breast oncology at UT Southwestern Medical Center, discusses the toxicities associated with antibody-drug conjugates (ADCs) used in breast cancer treatment at the 2023 San Antonio Breast Cancer Symposium.
Watch
Investigational Vaccine Has Non-Inferior Immune Response Compared to PCV20 for Pneumococcal Disease
December 13th 2023Clinical trial results show the immunogenicity, tolerability, and safety of V116 compared to a pneumococcal 20-valent conjugate vaccine for adults who had not previously received a pneumococcal vaccine.
Read More
Disparities Across European NEAT ID Centers Impact Implementation, Roll-Out of PrEP
December 13th 2023Both individual and structural barriers were the most common hindrances to PrEP roll-out, and the investigators emphasize that efforts to remove the obstacles as well as further research can help improve PrEP implementation.
Read More